RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
106 hedge funds and large institutions have $611M invested in RAPT Therapeutics in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 15 closing their positions.
1,548% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $664K
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
25% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 28
12% more funds holding
Funds holding: 95 → 106 (+11)
0.47% more ownership
Funds ownership: 11.67% → 12.14% (+0.47%)
3% less capital invested
Capital invested by funds: $628M → $611M (-$17.5M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$38M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.4M |
| 3 |
PA
Perceptive Advisors
New York
|
+$12.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.23M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$7.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$19.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$18.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.63M |
| 4 |
Walleye Capital
New York
|
-$6.26M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$5.58M |
RAPT Hedge Fund Activity: Q1 2023 in Review
106 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2023, worth a combined $611M — down 2.8% from $628M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new RAPT positions and 15 closed out — a net gain of 12 holders — while 35 added to existing stakes and 28 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $38M. The largest seller was Braidwell, exiting entirely with an estimated $19.8M sold.
- 106 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2023, up from 95 in Q4 2022.
- Funds reported $611M of RAPT Therapeutics stock for Q1 2023, down 2.8% quarter-over-quarter.
- 27 funds opened new RAPT Therapeutics positions in Q1 2023 and 15 closed out, a net change of +12 holders.
- The largest RAPT Therapeutics buyer in Q1 2023 was Fidelity Investments, an estimated $38M added.
- The largest RAPT Therapeutics seller in Q1 2023 was Braidwell, an estimated $19.8M sold.
Based on aggregated 13F filings for Q1 2023.